Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Surgical Treatment of Urinary Tumors
share announcement

Advances in Surgical Treatment of Urinary Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 3528

Special Issue Editors

Prof. Dr. Pierre I. Karakiewicz

E-Mail Website
Guest Editor
Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada
Interests: oncological urology; prostate cancer; prognostic markers; kidney cancer; bladder cancer; markers
Special Issues, Collections and Topics in MDPI journals
Dr. Simone Morra

E-Mail Website
Guest Editor
1. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
2. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
Interests: urologic oncology; bladder cancer; kidney cancer; prostate cancer; epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are delighted to present to you our Special Issue, focusing on "Advances in Surgical Treatment of Urinary Tumors." With great enthusiasm, we embark on this journey to explore the latest breakthroughs, innovative techniques and cutting-edge research in the realm of urologic oncology, aiming to improve the outcomes and quality of life for patients battling urinary tumors.

Urinary tumors, encompassing a diverse array of malignancies affecting the bladder, kidney, ureters and other urological structures, continue to pose significant challenges to medical practitioners worldwide. The burden of these conditions extends beyond the confines of the individual, affecting families and societies alike. However, in the face of these challenges, the medical community has shown relentless dedication to finding novel and effective solutions.

This Special Issue seeks to illuminate the significant strides made in the surgical management of urinary tumors, which have dramatically transformed the landscape of urologic oncology over recent years. From minimally invasive approaches to precision-guided interventions, the field has witnessed remarkable advancements that have revolutionized patient care, reduced morbidity and enhanced overall treatment outcomes.

Our distinguished panel of experts and researchers will meticulously curate the selection of articles, each contributing unique insights and perspectives into diverse aspects of surgical treatment for urinary tumors.

We extend our heartfelt gratitude to all the authors for their remarkable contributions and dedication to advancing the field of urologic oncology.

Prof. Dr. Pierre I. Karakiewicz
Dr. Simone Morra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • prostate cancer
  • kidney cancer
  • quality of life
  • urologic oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 499 KiB  
Article
Salvage Androgen Deprivation Therapy as Potential Treatment for Recurrence after Robot-Assisted Radical Prostatectomy
by Hiroshi Kano, Yoshifumi Kadono, Renato Naito, Tomoyuki Makino, Hiroaki Iwamoto, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi and Atsushi Mizokami
Cancers 2024, 16(7), 1304; https://doi.org/10.3390/cancers16071304 - 27 Mar 2024
Viewed by 1205
Abstract
Background: The efficacy of intermittent androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) is unknown, and its usefulness in Japanese practice needs to be investigated. Methods: We conducted a retrospective analysis of 85 patients who underwent RARP and [...] Read more.
Background: The efficacy of intermittent androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) is unknown, and its usefulness in Japanese practice needs to be investigated. Methods: We conducted a retrospective analysis of 85 patients who underwent RARP and were selected for intermittent ADT for postoperative recurrence at Kanazawa University Hospital between 2009 and 2019. Intermittent ADT was administered for 2 years. If prostate-specific antigen levels increased post-treatment, intermittent ADT was reinitiated. The median follow-up period was 47 months. Results: The 73 patients had completed the initial course of ADT, and 12 were under initial ADT. The 5-year castration-resistant prostate-cancer-free survival rates, cancer-specific survival, and overall survival were 92.7%, 98.3%, and 94.7%, respectively. A subgroup analysis of 69 patients who completed intermittent ADT was conducted to evaluate the BCR rate following initial ADT. The 5-year BCR-free survival rate was 53.2%. Multivariate analysis identified testosterone ≤ 0.03 ng/mL during ADT as the sole predictor of BCR after ADT. Conclusions: Salvage intermittent ADT may be an effective treatment option for BCR after RARP. In addition, it would be useful to confirm strong testosterone suppression as a criterion for transition to intermittent therapy. Full article
(This article belongs to the Special Issue Advances in Surgical Treatment of Urinary Tumors)
►▼ Show Figures

Figure 1

11 pages, 231 KiB  
Article
Robot-Assisted Radical Prostatectomy by the Hugo Robotic-Assisted Surgery (RAS) System and the da Vinci System: A Comparison between the Two Platforms
by Hsien-Che Ou, Lucian Marian, Ching-Chia Li, Yung-Shun Juan, Min-Che Tung, Hung-Jen Shih, Chin-Po Chang, Jian-Ting Chen, Che-Hsueh Yang and Yen-Chuan Ou
Cancers 2024, 16(6), 1207; https://doi.org/10.3390/cancers16061207 - 19 Mar 2024
Cited by 8 | Viewed by 1732
Abstract
Objective: In a previous study, we proved that an experienced urologist is more likely to adapt to the Hugo RAS system. Based on this, we further examine various parameters in this study. Parameters included in this study consisted of console time, functional outcomes, [...] Read more.
Objective: In a previous study, we proved that an experienced urologist is more likely to adapt to the Hugo RAS system. Based on this, we further examine various parameters in this study. Parameters included in this study consisted of console time, functional outcomes, and oncological outcomes. Materials and Methods: A total of 60 patients who underwent robot-assisted radical prostatectomy (RARP) performed by a single surgeon using the da Vinci (DV) system (n = 30) or the Hugo RAS system (n = 30) between March 2023 and August 2023 were included in the analysis. The intraoperative operative time was categorized into vesicourethral anastomosis time and overall console time. Functional and oncological outcomes were documented at the 1st and 3rd postoperative months. Parametric and non-parametric methods were adopted after checking skewness and kurtosis, and an α value of 5% was used to determine the significance. Results: The vesicourethral anastomosis time was significantly lengthened (Hedge’s g: 0.87; 95% confidence interval (CI): 0.34–1.39; J factor = 0.987). However, the overall console time was not affected. The functional (postoperative 3rd month: p = 0.130) and oncological outcomes (postoperative 3rd month: p = 0.103) were not significantly different. We also found that the adverse effect on surgical specimens and positive surgical margins was not affected (p = 0.552). Conclusion: During the process of adaptation, although intricate motions (such as the vesicourethral anastomosis time) would be lengthened, the overall console time would not change remarkably. In this process, the functional and oncological outcomes would not be compromised. This encourages urologists to adopt the Hugo RAS system in RARP if they have previous experiences of using the DV system, since their trifecta advantage would not be compromised. Full article
(This article belongs to the Special Issue Advances in Surgical Treatment of Urinary Tumors)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop